Precision BioSciences Files 8-K

TL;DR

PBIO filed an 8-K on Nov 10, 2025. Details pending.

AI Summary

On November 10, 2025, Precision BioSciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This filing indicates that Precision BioSciences, Inc. has submitted a current report to the SEC, which may contain updates on significant company events or financial information.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently poses a high risk.

Key Numbers

• 001-38841 — SEC File Number (Identifies the company's filing with the SEC.)
• 20-4206017 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Precision BioSciences, Inc. (company) — Registrant
• November 10, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Durham, North Carolina (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.000005 — ich registered Common Stock, par value $0.000005 per share DTIL The Nasdaq Capital Marke

Filing Documents

• dtil-20251110.htm (8-K) — 41KB
• a20251108precision_aasldxd.htm (EX-99) — 33KB
• 0001628280-25-051168.txt ( ) — 204KB
• dtil-20251110.xsd (EX-101.SCH) — 2KB
• dtil-20251110_lab.xml (EX-101.LAB) — 22KB
• dtil-20251110_pre.xml (EX-101.PRE) — 13KB
• dtil-20251110_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On November 10, 2025, Precision BioSciences, Inc. (the "Company") issued a press release to provide an update on its ELIMINATE-B clinical trial evaluating PBGENE-HBV for hepatitis B. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. As described in the accompanying press release, the Company will host a live webcast on November 11, 2025 at 8:00 a.m., Eastern Time, to review its ongoing ELIMINATE-B clinical trial. The dial-in conference call numbers for domestic and international callers are 1-800-715-9871 and 1-646-307-1963, respectively. The conference ID number for the call is 2525924. Participants may access the live webcast, and accompanying presentation materials, as well as the archived webcast on the Company's website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, this Item 7.01 (including the Press Release attached hereto as Exhibit 99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any registration statement or other filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events On November 10, 2025, the Company issued a press release announcing a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. The presentation includes data from the ongoing ELIMINATE-B Phase 1 study evaluating PBGENE-HBV, an in vivo gene editing therapy designed to eliminate cccDNA, the root cause of chronic Hepatitis B, and inactivate integrated HBV DNA. As of the October 31, 2025 data cutoff date, nine evaluable patients have been dosed across three ascending cohorts (0.2, 0.4, and 0.8 mg/kg), with a total of 22 administered doses. Key clinical findings from the late-breaking presentation include: Consistent antiviral activity across all treated patients regardless of baseline HBsAg Every participant receiving PBGENE-HBV exhibited measurable reductions in hepatitis B surface antigen (HBsAg) following treatment, confirming on-target antiviral effects across all dose levels. Importantly, consistent levels of antiviral activity were observed in patients regardless of baseline HBsAg levels ranging from 370 to 11,813 IU/mL, with no upper limit in the study. The magnitude and persistence of these declines increased with higher doses, providing evidence of cumulative antiviral activity from pre-planned repeat administrations without cumulative toxicities. Durable HBsAg reductions sustained over time In Cohort 1 (0.2 mg/kg), there was evidence of antiviral activity in all three patients with one patient showing a durable ~50% reduction in HBsAg 9 months after the initial dose of PBGENE-HBV and holding. In Cohort 2 (0.4 mg/kg), all three patients achieved durable HBsAg declines that were maintained for 8 weeks after the first administration and continue to show durable suppression following the third dose administration with HBsAg reductions up to 66%. Demonstrated dose-dependent antiviral activity Cohort 3 (0.8 mg/kg) demonstrated further dose-responsive antiviral effects,

Forward-Looking Statements

Forward-Looking Statements Current Report on Form 8-K, and except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Precision BioSciences, Inc. dated November 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRECISION BIOSCIENCES, INC. Date: November 10, 2025 By: /s/ John Alexander Kelly John Alexander Kelly Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR